AnalystsSilvan TuerkcanSilvan Tuerkcan's Stock Forecasts
AnalystsSilvan Tuerkcan
Analyst Ranking
Top 8%
#381 out of 5192 analysts
Average Return
+12.19%
Win Rate
47%90 out of 193
Risk vs Reward
Poor
Good
Silvan Tuerkcan's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Terns Pharmaceuticals IncTERN | +1,292.99% | $2.71 | $37.75 | 2025-04-20 - 2026-02-12 | Buy |
Terns Pharmaceuticals IncTERN | +403.33% | $7.50 | $37.75 | 2025-10-22 - 2026-02-12 | Buy |
Intellia Therapeutics IncNTLA | +352.88% | $13.35 | $60.46 | 2020-02-27 - 2021-02-26 | Buy |
Logicbio Therapeutics IncLOGC2 | +345.16% | $0.47 | $2.07 | 2022-05-09 - 2022-11-15 | Buy |
Taysha Gene Therapies IncTSHA | +296.41% | $0.72 | $2.87 | 2023-03-29 - 2024-03-28 | Buy |
Silvan Tuerkcan Analyst Color
Get additional color on Silvan Tuerkcan's coverage of popular stocks
Silvan Tuerkcan's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Crispr Therapeutics AgCRSP | 16 | Buy | $86.00 | +75.76% | Reiterates | 2 months ago |
Terns Pharmaceuticals IncTERN | 15 | Buy | $57.00 | +50.99% | Maintains | 2 months ago |
Nuvation Bio IncNUVB | 5 | Buy | $10.00 | +72.71% | Maintains | 3 months ago |
Engene Holdings IncENGN | 5 | Buy | $21.00 | +111.27% | Maintains | 3 months ago |
Intellia Therapeutics IncNTLA | 10 | Buy | $21.00 | +80.72% | Maintains | 3 months ago |
Taysha Gene Therapies IncTSHA | 14 | Buy | $8.00 | +72.04% | Maintains | 3 months ago |
Benitec Biopharma IncBNTC | 14 | Buy | $22.00 | +94.00% | Maintains | 3 months ago |
Jasper Therapeutics IncJSPR | 7 | Buy | $6.00 | +412.82% | Maintains | 5 months ago |
Phreesia IncPHR | 1 | Buy | $34.00 | +186.68% | Maintains | 5 months ago |
Ideaya Biosciences IncIDYA | 2 | Buy | $45.00 | +42.77% | Maintains | 5 months ago |
Exelixis IncEXEL | 21 | Buy | $50.00 | +17.10% | Reiterates | 7 months ago |
Solid Biosciences IncSLDB | 3 | Buy | $15.00 | +146.71% | Reiterates | 8 months ago |
Prime Medicine IncPRME | 3 | Buy | $6.00 | +80.72% | Maintains | 9 months ago |
Foghorn Therapeutics IncFHTX | 3 | Buy | $9.00 | +71.10% | Reiterates | 9 months ago |
Vor Biopharma IncVOR | 12 | Hold | $120.00 | +818.13% | Downgrades | 9 months ago |
Acrivon Therapeutics IncACRV | 5 | Buy | $17.00 | +975.95% | Reiterates | a year ago |
Elevation Oncology IncELEV | 7 | Hold | $7.00 | +1,817.81% | Downgrades | a year ago |
Context Therapeutics IncCNTX | 1 | Buy | $4.00 | N/A | Initiates Coverage On | a year ago |
Relay Therapeutics IncRLAY | 10 | Buy | $21.00 | N/A | Reiterates | a year ago |
Macrogenics IncMGNX | 10 | Buy | $8.00 | N/A | Maintains | 2 years ago |
Cellectis SaCLLS | 6 | Buy | $6.00 | N/A | Reiterates | 2 years ago |
Notable Labs LtdNTBLQ | 3 | Buy | $9.00 | N/A | Reiterates | 2 years ago |
Mondaycom LtdMNDY | 3 | Buy | $280.00 | N/A | Maintains | 2 years ago |
Mirati Therapeutics IncMRTX | 8 | Buy | $82.00 | N/A | Maintains | 2 years ago |
Generation Bio CoGBIO | 6 | Buy | $70.00 | N/A | Reiterates | 3 years ago |
Two Harbors Investment CorpTWO | 1 | Buy | $18.00 | N/A | Maintains | 3 years ago |
Logicbio Therapeutics IncLOGC2 | 3 | Buy | $3.00 | N/A | Maintains | 4 years ago |
Turning Point Therapeutics IncTPTX | 2 | Hold | N/A | N/A | Downgrades | 4 years ago |
Constellation Pharmaceuticals IncCNST | 1 | Hold | N/A | N/A | Downgrades | 5 years ago |
Seagen IncSGEN | 2 | Buy | $200.00 | N/A | Maintains | 6 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.